ReviewIntegrative cancer therapies
Cannabis, Cannabinoids and Cannabis-Based Medicines in Cancer Care.
Review in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 48 citations in OpenAlex.
- Reimagining Cannabidiol Delivery Through Carbon Nanodots.Molecules (Basel, Switzerland) · 2026Review
- Readiness to Use Medicinal Marijuana in the Practices of Polish Family Physicians.Journal of clinical medicine · 2026Article
- Ewing sarcoma-related pain: potential role of medical cannabis monotherapy in symptom management - a case report.Journal of cannabis research · 2026Article
- Survey of MaineHealth Cancer Care Network Providers on Cannabis Use: Preparation for Studies Sponsored by the National Cancer Institute.Journal of Maine Medical Center · 2026Article
- Perioperative Repercussions of Cannabis Use-Implications for GI Endoscopy Sedation.Journal of clinical medicine · 2025Review
- Comparative Effects of THC and CBD on Chemotherapy-Induced Peripheral Neuropathy: Insights from a Large Real-World Self-Reported Dataset.Biomedicines · 2025Article
- State of the Science: Health Care Provider Communication of Cannabis Use Among Adults Living with Cancer.Journal of cancer education : the official journal of the American Association for Cancer Education · 2025Review
- Recreational drugs repurposed for medicinal use-cannabis.CNS spectrums · 2025Review
- Cannabis Use for Medical or Non-Medical Purposes in a Sample of Young Adult Cancer Survivors in the United States.Cannabis (Albuquerque, N.M.) · 2025Article
- Evaluating Online Cannabis Health Information for Thai Breast Cancer Survivors Using the Quality Evaluation Scoring Tool (QUEST): Mixed Method Study.JMIR cancer · 2024Article
- Adverse events associated with the use of cannabis-based products in people living with cancer: a systematic scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Medical cannabis: From research breakthroughs to shifting public perceptions and ensuring safe use.Integrative medicine research · 2024Review
- Clinical Benefits and Safety of Medical Cannabis Products: A Narrative Review on Natural Extracts.Pain and therapy · 2024Review
- Article
- Drug Interactions of Tetrahydrocannabinol and Cannabidiol in Cannabinoid Drugs.Deutsches Arzteblatt international · 2023Review
- In Vitro Evidence of Selective Pro-Apoptotic Action of the Pure Cannabidiol and Cannabidiol-Rich Extract.Molecules (Basel, Switzerland) · 2023Article
- Molecular Advances on Cannabinoid and Endocannabinoid Research.International journal of molecular sciences · 2023Article
- Cannabis use prevalence, patterns, and reasons for use among patients with cancer and survivors in a state without legal cannabis access.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Review
- Should oncologists trust cannabinoids?Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As medical cannabis becomes legal in more states, cancer patients are increasingly interested in the potential utility of the ancient botanical in their treatment regimen. Although eager to discuss cannabis use with their oncologist, patients often find that their provider reports that they do not have adequate information to be helpful. Oncologists, so dependent on evidence-based data to guide their treatment plans, are dismayed by the lack of published literature on the benefits of medical cannabis. This results largely from the significant barriers that have existed to effectively thwart the ability to conduct trials investigating the potential therapeutic efficacy of the plant. This is a narrative review aimed at clinicians, summarizing cannabis phytochemistry, trials in the areas of nausea and vomiting, appetite, pain and anticancer activity, including assessment of case reports of antitumor use, with reflective assessments of the quality and quantity of evidence. Despite preclinical evidence and social media claims, the utility of cannabis, cannabinoids or cannabis-based medicines in the treatment of cancer remains to be convincingly demonstrated. With an acceptable safety profile, cannabis and its congeners may be useful in managing symptoms related to cancer or its treatment. Further clinical trials should be conducted to evaluate whether the preclinical antitumor effects translate into benefit for cancer patients. Oncologists should familiarize themselves with the available database to be able to better advise their patients on the potential uses of this complementary botanical therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.